secwatch.observer — SEC 8-K summary
======================================

Issuer:     WEST PHARMACEUTICAL SERVICES INC (WST)
CIK:        0000105770
Form:       8-K
Filed at:   2021-07-29T23:59:59+00:00
Accession:  0000105770-21-000050
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

West Pharma Q2 net sales $723.6M (+37.3%), EPS $2.47 (+104%); raises full-year guidance
--------------------------------------------------------------------------------

- Net sales $723.6M, up 37.3% (organic +30.6%); reported diluted EPS $2.47, up 104%.
- Adjusted diluted EPS $2.46, up 97%; Proprietary Products segment sales up 47%, driven by HVP components.
- Raises FY2021 net sales guidance to $2.760-$2.785B (from $2.630-$2.655B) and adjusted EPS to $8.05-$8.20 (from $6.95-$7.10).
- Strong demand from COVID-19 vaccines and base business; new capital spending tranche for HVP capacity expansion in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/105770/000010577021000050/0000105770-21-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/105770/000010577021000050/wst-20210729.htm
  HTML page:      https://secwatch.observer/filing/0000105770-21-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer